2008 Letter to the Shareholder and Investor Profile
Safe Harbor:
The enclosed documents contain forward-looking statements about Vertex and its drug development candidates, including statements regarding: ongoing and planned drug development activities for telaprevir, VX-770, VX-809, our HCV polymerase inhibitor compounds and our other drug candidates; the data that may be generated by our ongoing and planned clinical trials, and in particular our belief that data from our Phase 3 clinical trials of telaprevir will enable the filing of a New Drug Application in the second half of 2010; the potential for our drug candidates to improve how serious diseases are treated; our financial strategy including the balancing of investment decisions and financial strength; and our plan to use certain assets as a source of revenue and cash flow to help support our operating investment. While we believe that the forward-looking statements contained in these documents are accurate, there are a number of factors that could cause actual events or results to differ materially from those indicated by such forward-looking statements. These risks include the risk that any one or more of our internal or external drug development programs will not proceed as planned for technical, scientific or commercial reasons or due to patient enrollment issues or based on new information from clinical, nonclinical or other sources, that data generated from our advanced clinical trials will be insufficient to gain regulatory approval for commercialization, that our investment decisions will not be supported by revenue and cash flow sufficient to meet our financial expectations and other risks listed under Risk Factors in our reports on Form 10-K and Form 10-Q filed with the Securities and Exchange Commission and available through our website at www.vrtx.com.